Ex-OpenAI Talent Builds $3.8B AI Drug Discovery Startup Chai Discovery

rishabh16_ · x · 2026-08-05

Josh Meier, co-founder & CEO of Chai Discovery, shared his vision in an interview. After training LLMs at OpenAI and building the first protein transformer at Meta, he now leads Chai Discovery. The 2-year-old, 30-person company, valued at $3.8B, focuses on AI drug design for clients like Eli Lilly, Pfizer, and Novartis. He views AI's potential to cure complex diseases as the greatest argument for rapid development and a moral obligation.

Original post →

More from Companies & People

Companies & People channel →